An overview on recent patents and technologies on nanoparticles for nucleic acid delivery

Apr 5, 2024Expert opinion on therapeutic patents

Recent patents and technologies for using nanoparticles to deliver genetic material

AI simplified

mRNA Technology on OpenScience ↗PubMed ↗DOI ↗

Abstract

Investment in nanoparticles for nucleic acid delivery has significantly surged in recent years.

Nucleic acid-based therapeutics show potential for treating genetic diseases and improving vaccines.
Nanoparticles serve as important carriers to enhance the delivery of nucleic acids to target cells.
A comprehensive review of patents reveals trends in compositions, applications, and manufacturing related to nanoparticles.
Key challenges in clinical translation include the need for strong clinical evidence and regulatory compliance.
The review aims to foster global engagement among researchers to advance nanoparticle-based delivery technologies.

AI simplified

INTRODUCTION: Nucleic acid-based therapeutics offer groundbreaking potential for treating genetic diseases and advancing next-generation vaccines. Despite their promise, challenges in efficient delivery persist due to the properties of nucleic acids. Nanoparticles (NPs) serve as vital carriers, facilitating effective delivery to target cells, and addressing these challenges. Understanding the global landscape of patents in this field is essential for fostering innovation and guiding decision-making for researchers, the pharmaceutical industry, and regulatory agencies.

AREAS COVERED: This review provides a comprehensive overview of patent compositions, applications, and manufacturing aspects concerning NPs as nucleic acid delivery systems. It delves into temporal trends, protection locations, market dynamics, and the most influential technological domains. In this work, we provide valuable insights into the advancements and potential of NP-based nucleic acid delivery systems, with a special focus on their pivotal role in advancing cutting-edge therapeutic solutions.

EXPERT OPINION: Investment in NPs for nucleic acid delivery has significantly surged in recent years. However, translating these therapies into clinical practice faces obstacles, including the need for robust clinical evidence, regulatory compliance, and streamlined manufacturing processes. To address these challenges, our review article summarizes recent advances. We aim to engage researchers worldwide in the development of these promising technologies.

Full Text

Full text is available at the source.

View full text ↗

An overview on recent patents and technologies on nanoparticles for nucleic acid delivery

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief